Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.6K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

298
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
298
Liver Regeneration01:24

Liver Regeneration

3.9K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.

Kidney360·2023
Same author

Reduced metabolic flexibility is a predictor of weight gain among liver transplant recipients.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2023
Same author

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.

Gastroenterology·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Noninvasive Assessment of Liver Fibrosis in NAFLD.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same journal

Cancer immunotherapy with oncolytic myxoma virus.

Advances in cancer research·2026
Same journal

Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents.

Advances in cancer research·2026
Same journal

Advancing clinical translation of oncolytic adenoviruses.

Advances in cancer research·2026
Same journal

Operation oncolysis: Reoviruses in the theater of cancer war.

Advances in cancer research·2026
Same journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same journal

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Advances in cancer research·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K

NAFLD-related HCC.

Bubu A Banini1, Arun J Sanyal2

  • 1Section of Digestive Diseases, Yale University, New Haven, CT, United States.

Advances in Cancer Research
|February 13, 2021
PubMed
Summary
This summary is machine-generated.

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver cancer (HCC). Rising rates of NAFLD, obesity, and type 2 diabetes are fueling this increase, necessitating a deeper understanding of the molecular links.

Keywords:
CirrhosisFibrosisHepatocellular carcinomaInsulin resistanceMetabolic syndromeNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisObesity

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.5K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.7K

Related Experiment Videos

Last Updated: Nov 17, 2025

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.5K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.7K

Area of Science:

  • Hepatology
  • Oncology
  • Metabolic Diseases

Background:

  • Nonalcoholic fatty liver disease (NAFLD) incidence has tripled in 30 years, paralleling a similar rise in liver cancer (hepatocellular carcinoma, HCC).
  • NAFLD is projected to affect 101 million US adults by 2030, with global increases anticipated.
  • Metabolic syndrome, including obesity and type 2 diabetes mellitus, is strongly associated with NAFLD and subsequent HCC development.

Purpose of the Study:

  • To summarize current evidence linking NAFLD, metabolic syndrome, and HCC.
  • To elucidate the molecular mechanisms connecting metabolic disorders to liver cancer.

Main Methods:

  • Literature review of epidemiological data and molecular studies.
  • Analysis of the relationship between NAFLD, obesity, type 2 diabetes, and hepatocarcinogenesis.
  • Description of key molecular pathways involved.

Main Results:

  • NAFLD is a significant driver of the increasing HCC incidence.
  • Obesity and type 2 diabetes are key components of metabolic syndrome contributing to HCC risk in NAFLD patients.
  • Specific molecular mechanisms linking metabolic dysfunction to liver cancer initiation and progression have been identified.

Conclusions:

  • NAFLD represents a critical public health challenge due to its strong association with HCC.
  • Understanding the molecular underpinnings of NAFLD-associated HCC is crucial for developing targeted prevention and treatment strategies.
  • Addressing metabolic syndrome components like obesity and type 2 diabetes is vital in mitigating the growing burden of liver cancer.